Palatin Technologies, Inc. Reports Fourth Quarter and Fiscal Year End 2011 Results
CRANBURY, N.J., Sept. 22, 2011 /PRNewswire/ — Palatin Technologies, Inc. (NYSE Amex: PTN), a biopharmaceutical company developing bremelanotide for sexual dysfunction indications and PL-3994 for acute asthma and other indications, today announced results for its fourth quarter and fiscal year ended June 30, 2011. Recent Highlights Palatin initiated enrollment in its Phase 2B trial …
Palatin Technologies, Inc. Reports Fourth Quarter and Fiscal Year End 2011 Results Read More »